105
Views
37
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE Cellular and Molecular Biology

Urocortin's Inhibition of Tumor Growth and Angiogenesis in Hepatocellular Carcinoma via Corticotrophin-Releasing Factor Receptor 2

, , , , , & show all
Pages 359-368 | Published online: 11 Jun 2009

REFERENCES

  • Llovet J. M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907–1917
  • Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–1186
  • Bergers G., Benjamin L. E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3(6)401–410
  • Cross M. J., Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001; 22(4)201–207
  • Tomita N., Morishita R., Taniyama Y., Koike H., Aoki M., et al. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 2003; 107(10)1411–1417
  • Vaughan J., Donaldson C., Bittencourt J., Perrin M. H., Lewis K., et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995; 378(6554)287–292
  • Perrin M. H., Vale W. W. Corticotropin releasing factor receptors and their ligand family. Ann N Y Acad Sci 1999; 885: 312–328
  • Fekete E. M., Zorrilla E. P. Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol 2007; 28(1)1–27
  • Simoncini T., Apa R., Reis F. M., Miceli F., Stomati M., et al. Human umbilical vein endothelial cells: a new source and potential target for corticotropin-releasing factor. J Clin Endocrinol Metab 1999; 84(8)2802–2806
  • Jain V., Longo M., Ali M., Saade G. R., Chwalisz K., et al. Expression of receptors for corticotropin-releasing factor in the vasculature of pregnant rats. J Soc Gynecol Investig 2000; 7(3)153–160
  • Bale T. L., Giordano F. J., Hickey R. P., Huang Y., Nath A. K., et al. Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci USA 2002; 99(11)7734–7739
  • Tao J., Chen J., Wu Y., Li S. Urocortin reduces the viability of adult rat vascular smooth muscle cells via inhibiting L-type calcium channels. Peptide 2005; 26(11)2239–2245
  • Tanigawa N., Lu C., Mitsui T., Miura S. Quantitation of sinusoid-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology 1997; 26(5)1216–1223
  • Gulec S. A., Woltering E. A. A new in vitro assay for human tumor angiogenesis: three-dimensional human tumor angiogenesis assay. Ann Surg Onclo 2004; 11(1)99–104
  • Iino K., Sasano H., Oki Y., Andoh N., Shin R. W., et al. Urocortin expression in human pituitary gland and pituitary adenoma. J Clin Endocrinol Metab 1997; 82(11)3842–3850
  • Arcuri F., Cintorino M., Florio P., Floccari F., Pergola L., et al. Expression of urocortin mRNA and peptide in the human prostate and in prostatic adenocarcinoma. The Prostate 2002; 52(3)167–172
  • Florio P., De Falco G., Leucci E., Torricelli M., Torres P. B., et al. Urocortin expression is downregulated in human endometrial carcinoma. J Endocrinol 2006; 190(1)99–105
  • Graziani G., Tentori L., Portarena I., Barbarino M., Tringali G., et al. CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 2002; 143(3)807–813
  • Carlson K. W., Nawy S. S., Wei E. T., Sadée W., Filov V. A., et al. Inhibition of mouse melanoma cell proliferation by corticotrophin-releasing hormone and its analogs. Anticancer Res 2001; 21(2A)1173–1179
  • Slominski A., Roloff B., Zbytek B., Wei E. T., Fechner K., et al. Corticotropin-releasing hormone and related peptides can act as bioregulatory factors in human keratinocytes. In Vitro Cell Dev Bio Anim 2000; 36(3)211–216
  • Graziani G., Tentori L., Muzi A., Vergati M., Tringali G., et al. Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol 2007; 264(1–2)44–49
  • Arbiser J. L., Karalis K., Viswanathan A., Koike C., Anand-Apte B., et al. Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin. J Invest Dermatol 1999; 113(5)838–842
  • Yang Y., Park H., Yang Y., Kim T. S., Bang S. I., et al. Enhancement of cell migration by corticotropin releasing hormone through ERK1/2 pathway in murine melanoma cell line, B16F10. Exp Dermatol 2006; 16(1)22–27
  • Radulovic M., Hippel C., Spiess J. Corticotropin-releasing factor (CRF) rapidly suppresses apoptosis by acting upstream of the activation of caspases. J Neurochem 2003; 84(5)1074–1085
  • Cao J., Papadopoulou N., Kempuraj D., Boucher W. S., Sugimoto K., et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 2005; 174(12)7665–7675

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.